Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan in TROP2-Positive Advanced Biliary Tract Cancer
NCT07701122Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jul 2027
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in biliary tract cancer (BTC). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07701122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701122.